|
SX-listed medical cannabis firm AusCann Group Holdings Ltd has successfully completed the placement of 30.4 million shares that netted the company A$33.4 million ($25 million) in fresh capital. In a disclosure to the Australia Securities Exchange, AusCann said the placement was made to investors from North America and Australia, including AusCann’s major shareholder, Canopy Growth Corporation, which, following completion of the placement, will increase its ownership to 11.2 per cent. The placement represents 30.4 million new fully paid ordinary shares in AusCann under an issue price of A$1.10, an 11.7 per cent discount on the weighted average price of its shares over the 15-day prior period of trade. Based in Australia, AusCann seeks to produce clinically validated cannabinoid medicines. It initially targets medications for neuropathic and chronic pain in Australia and Chile, while exploring global export opportunities. Read more at: https://www.dealstreetasia.com/stories/auscann-cannabis-plac… |
|
| aus der Diskussion: | AusCann !!! |
| Autor (Datum des Eintrages): | meisterpeppo (05.07.18 15:00:23) |
| Beitrag: | 15 von 196 (ID:58144982) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |